1. Academic Validation
  2. FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression

FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression

  • BMC Cancer. 2024 Mar 9;24(1):326. doi: 10.1186/s12885-024-12075-2.
Jie Wang # 1 2 Chunlin Wang # 1 2 Anling Hu 1 2 Kunlin Yu 1 2 Yi Kuang 1 2 Babu Gajendran 1 3 Eldad Zacksenhaus 4 5 Klarke Michael Sample 6 Xiao Xiao 1 2 Wuling Liu 7 8 Yaacov Ben-David 9 10
Affiliations

Affiliations

  • 1 State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang-550014, Guizhou, People's Republic of China.
  • 2 Natural Products Research Center of Guizhou Province, High Tech Zone, Province Science City, Baiyun District, Guiyang, 550014, China.
  • 3 School of Pharmaceutical Sciences, Guizhou Medical University, Guizhou Province, Guiyang, 550025, People's Republic of China.
  • 4 Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • 5 Division of Advanced Diagnostics, Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
  • 6 eBond Pharmaceutical Technology Ltd, Chengdu, Sichuan, People's Republic of China.
  • 7 State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang-550014, Guizhou, People's Republic of China. emmalao@163.com.
  • 8 Natural Products Research Center of Guizhou Province, High Tech Zone, Province Science City, Baiyun District, Guiyang, 550014, China. emmalao@163.com.
  • 9 State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang-550014, Guizhou, People's Republic of China. yaacovbendavid@hotmail.com.
  • 10 Natural Products Research Center of Guizhou Province, High Tech Zone, Province Science City, Baiyun District, Guiyang, 550014, China. yaacovbendavid@hotmail.com.
  • # Contributed equally.
Abstract

Background: FLI1 is an oncogenic transcription factor that promotes diverse malignancies through mechanisms that are not fully understood. Herein, FLI1 is shown to regulate the expression of Ubiquitin Associated and SH3 Domain Containing A/B (UBASH3A/B) genes. UBASH3B and UBASH3A are found to act as an oncogene and tumor suppressor, respectively, and their combined effect determines erythroleukemia progression downstream of FLI1.

Methods: Promoter analysis combined with luciferase assays and chromatin immunoprecipitation (ChIP) analysis were applied on the UBASH3A/B promoters. RNAseq analysis combined with bioinformatic was used to determine the effect of knocking-down UBASH3A and UBASH3B in leukemic cells. Downstream targets of UBASH3A/B were inhibited in leukemic cells either via lentivirus-shRNAs or small molecule inhibitors. Western blotting and RT-qPCR were used to determine transcription levels, MTT assays to assess proliferation rate, and flow cytometry to examine apoptotic index.

Results: Knockdown of FLI1 in erythroleukemic cells identified the UBASH3A/B genes as potential downstream targets. Herein, we show that FLI1 directly binds to the UBASH3B promoter, leading to its activation and leukemic cell proliferation. In contrast, FLI1 indirectly inhibits UBASH3A transcription via GATA2, thereby antagonizing leukemic growth. These results suggest oncogenic and tumor suppressor roles for UBASH3B and UBASH3A in erythroleukemia, respectively. Mechanistically, we show that UBASH3B indirectly inhibits AP1 (FOS and JUN) expression, and that its loss leads to inhibition of Apoptosis and acceleration of proliferation. UBASH3B also positively regulates the Syk gene expression and its inhibition suppresses leukemia progression. High expression of UBASH3B in diverse tumors was associated with worse prognosis. In contrast, UBASH3A knockdown in erythroleukemic cells increased proliferation; and this was associated with a dramatic induction of the HSP70 gene, HSPA1B. Accordingly, knockdown of HSPA1B in erythroleukemia cells significantly accelerated leukemic cell proliferation. Accordingly, overexpression of UBASH3A in different cancers was predominantly associated with good prognosis. These results suggest for the first time that UBASH3A plays a tumor suppressor role in part through activation of HSPA1B.

Conclusions: FLI1 promotes erythroleukemia progression in part by modulating expression of the oncogenic UBASH3B and tumor suppressor UBASH3A.

Keywords

AP1; FLI1; HSPA1B; Leukemia proliferation; Oncogene; SYK; Transcriptional regulation; Tumor suppressor; UBASH3A; UBASH3B.

Figures
Products